Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Moderna discusses COVID-19 vaccine manufacturing with Nexus Pharmaceuticals: sources

CoronavirusApr 14, 2021 04:35PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: COVID-19 vaccination at Glangwili General Hospital in Carmarthen

By Nandita Bose

WASHINGTON (Reuters) - Moderna (NASDAQ:MRNA) Inc, looking to boost production of its COVID-19 vaccine, met with Nexus Pharmaceuticals to discuss manufacturing the shot at the company's new plant in Wisconsin, which has the capacity to process and fill 30 million doses a month, sources with knowledge of the matter said.

The meeting between Moderna and the maker of specialty drugs took place on Tuesday, the sources said.

Senior White House and administration officials, including David Kessler, chief science officer for Covid response and Tim Manning, COVID-19 supply coordinator, have facilitated introductions and discussions between Nexus, Moderna and Johnson & Johnson (NYSE:JNJ), according to two sources.

Even though President Joe Biden has said there would be enough vaccines for all adults in the United States by May, there could still be supply concerns later in the year, particularly if people require a booster shot at some point to protect against concerning virus variants that may be circulating.

It remains unclear if the meeting will result in a deal to manufacture vaccines at the Nexus plant, the sources said. Funding from the Defense Production Act will be essential for a deal to work, one of the sources said.

"Moderna is looking to produce more vaccines ... and Nexus has the capacity to do it," one of the sources said.

Illinois-based Nexus does not currently manufacture COVID-19 vaccines but has built capacity to ramp up production at their new plant in Wisconsin, one of the sources said.

The White House declined comment on the meeting. Nexus and Moderna also declined comment.

On Tuesday, Moderna said it was on track to deliver 300 million doses to the United States by the end of July, in line with its commitments. Moderna delivered 45 million vaccines to U.S. states in March.

Moderna's chief executive on Wednesday said the company was unlikely to markedly speed up its vaccine production in the next few months, though it expects the output to have increased significantly by 2022.

The Biden administration has previously brokered commitments among rival drugmakers to boost COVID-19 vaccine production.

In March, Biden announced that Merck & Co will help manufacture Johnson & Johnson's single-shot coronavirus vaccine.

Despite its efforts there have been significant setbacks.

For example, some 15 million doses of J&J's vaccine were wasted due to contamination with ingredients from AstraZeneca (NASDAQ:AZN)'s shot at a Baltimore plant that was producing both. That Emergent BioSolutions facility will now produce only the J&J shot.

Separately, U.S. federal health agencies on Tuesday recommended pausing use of the J&J COVID-19 vaccine while it looks into six cases of rare brain blood clots in women under age 50 who received the shot.

Moderna discusses COVID-19 vaccine manufacturing with Nexus Pharmaceuticals: sources
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email